Hiromi Kan

Efficacy and safety of sitagliptin for the treatment of nonalcoholic fatty liver disease with type 2 diabetes mellitus.

Takayuki Fukuhara, Hideyuki Hyogo, Hidenori Ochi et al. · PubMed · 2014 · 63 citations

Medicine, Pharmacology, Pharmacotherapy +16

Development of hepatocellular carcinoma in patients with hepatitis C virus infection who achieved sustained virological response following interferon therapy: A large‐scale, long‐term cohort study

Yuko Nagaoki, Hiroshi Aikata, Norihito Nakano et al. · Journal of Gastroenterology and Hepatology · 2015 · 60 citations

Medicine, Infectious Diseases, Hepatology +16

The risks of hepatocellular carcinoma development after HCV eradication are similar between patients treated with peg-interferon plus ribavirin and direct-acting antiviral therapy

Yuko Nagaoki, Michio Imamura, Hiroshi Aikata et al. · PLoS ONE · 2017 · 57 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Efficacy and safety of the anticoagulant drug, danaparoid sodium, in the treatment of portal vein thrombosis in patients with liver cirrhosis

Noriaki Naeshiro, Hiroshi Aikata, Hideyuki Hyogo et al. · Hepatology Research · 2014 · 46 citations

Medicine, Pharmacology, Pharmacotherapy +11

Role of <scp>3‐D</scp> conformal radiotherapy for major portal vein tumor thrombosis combined with hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma

Hatsue Fujino, Tomoki Kimura, Hiroshi Aikata et al. · Hepatology Research · 2014 · 44 citations · Full text

Medicine, Oncology, Surgery +15